Anto Biosciences key facts
as of Oct 2026- Developer of a multimodal foundation model designed to make the gut microbiome computable and improve understanding of drug response.
- Anto Biosciences is valued at approximately $30.0M as of Oct 2026 (last reported valuation).
- It has raised $600K; the latest was Early Stage VC ($100K) in Jan 2026.
- Notable investors include Y Combinator, RRE Ventures, Ritual Capital, Massive Tech Ventures, Standard Partners — 16 tracked in total.
- Status: Privately Held (backing).
Anto Biosciences's last reported valuation, Jan 2026. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch Anto Biosciences: the Monday email on marks, rounds and moves
Anto Biosciences funding rounds
No funding rounds for Anto Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Anto Biosciences
16+Membership and data by Private Market View
Anto Biosciences valuation
Anto Biosciences's last reported valuation was $30 million in Jan 2026. No priced round, secondary trade or fund mark has surfaced since.
Anto Biosciences investors
16 investors are on record for Anto Biosciences, including Y Combinator, RRE Ventures, Ritual Capital and Massive Tech Ventures.
About Anto Biosciences
Developer of a multimodal foundation model designed to make the gut microbiome computable and improve understanding of drug response. The company offers a platform that models microbial communities and predicts drug toxicity and efficacy across diverse populations, enabling pharmaceutical researchers to design and optimize molecules for broader effectiveness and reduced failure rates.
- Sector
- Business Products and Services (B2B)
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 2
- Website
- anto.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.